Sandoz Canada

As a Canadian leader in off-patent medicines, Sandoz Canada has a product portfolio that includes over 700 generics and biosimilars spanning multiple therapeutic areas, such as anti-infective, cardiovascular, central nervous system, immunology and oncology. In 2025, 59 million Sandoz prescriptions were issued in Canada (source: IQVIA Compuscript TRx, MAT 2025). Sandoz Canada employs 300 people across the country and at its head office in Saint-Hubert, Quebec. It is a trusted partner for pharmacists, physicians and hospitals for quality medicine and outstanding customer service and is committed to ensuring a reliable supply. For more information about Sandoz Canada, visit www.sandoz.ca.



Contact Information
Chef, Communications corporatives, [email protected]; Sophie Levasseur, +1 263 788-3835
Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected.

Latest

Feb 02, 2026, 08:00 ET Sandoz Canada launches first ophthalmology biosimilar

Sandoz Canada expands portfolio launching Enzeevu®, company's first ophthalmology biosimilar Enzeevu® is approved for all indications of reference medicine EYLEA® 1, including neovascular age-related ...

Oct 01, 2025, 11:06 ET Sandoz Canada launches PrSandoz® Sacubitril-Valsartan, expanding access to heart failure treatments

PrSandoz® Sacubitril-Valsartan is generic indicated for treatment of heart failure with reduced ejection fraction (HFrEF), which currently affects approximately 375,000 Canadians1 As reference...

Aug 27, 2025, 07:30 ET Sandoz welcomes Quebec government support for Boucherville plant modernization project

Sandoz underlines importance of Delpharm Boucherville plant modernization project, made possible by total investment of CAD 220 million Amount includes joint investments from provincial and federal...

Nov 27, 2023, 07:01 ET Sandoz Canada announces first ever list of Top 100 most important medicines, from a clinical standpoint, for Canadian patients

Working with a group of medical experts across the country, Sandoz Canada has put together a list of the Top 100 most important medicines from a clinical standpoint according to the criticality of...

Oct 04, 2023, 09:00 ET Sandoz enters new era as standalone global leader in generic and biosimilar medicines

Spin-off from Novartis successfully completed with first trading day today on SIX Swiss Exchange; Sandoz shares included in key market indices Standalone Sandoz committed to extend leadership in...

Apr 19, 2018, 07:00 ET Four Canadian provinces add ErelziTM (etanercept) to provincial drug plans for the treatment of multiple inflammatory diseases

Erelzi has been added to drug formularies in Manitoba, Saskatchewan, Alberta and Newfoundland based on specific criteria for the treatment of moderate to severe rheumatoid arthritis and for reducing...

Mar 07, 2018, 07:00 ET Sandoz Canada launches two new generic therapies for hypertension

Sandoz® Perindopril Erbumine and Sandoz® Perindopril Erbumine/Indapamide are generic alternatives to Coversyl and Coversyl Plus. They are part of the angiotensin family converting enzyme, typically...

Feb 05, 2018, 07:00 ET Quebec adds Erelzi™ (etanercept) to provincial drug plans for the treatment of multiple inflammatory diseases

Erelzi™ has been added to the Quebec Drug Insurance Plan based on specific criteria for the treatment of moderate to severe rheumatoid arthritis and for reducing signs and symptoms of active...

Jan 09, 2018, 07:30 ET Ontario has added Erelzi™ (etanercept) to public drug plan for the treatment of multiple inflammatory diseases

Erelzi™ has been added to public drug plan based on specific criteria in Ontario for the treatment of moderate to severe rheumatoid arthritis and for reducing signs and symptoms of active ankylosing...

Nov 16, 2017, 14:10 ET British Columbia and Prince Edward Island become the first provinces to add Erelzi™ (etanercept) to public drug plans for the treatment of multiple inflammatory diseases

Erelzi™, has been added to public drug plans based on specific criteria in British Columbia and Prince Edward Island for the treatment of moderate to severe rheumatoid arthritis and for reducing...

Aug 02, 2017, 07:00 ET Sandoz Erelzi™ (etanercept) receives positive reimbursement recommendation from Common Drug Review for treatment of multiple inflammatory diseases

Positive recommendation is based on the condition that ErelziTM be reimbursed in a manner similar to Enbrel® for the treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, and Polyarticular...

May 16, 2012, 10:30 ET Sandoz Canada makes strong progress in supply of critical medicines

BOUCHERVILLE, QC, May 16, 2012 /CNW Telbec/ - Sandoz Canada continues to make strong progress in its efforts to maintain a reliable supply of essential medicines following the temporary slow-down in...

Mar 26, 2012, 15:47 ET Sandoz Canada restarts shipments of 2mg/mL, 1 mL morphine ampoules with 100% product passing inspection

BOUCHERVILLE, QC, March 26, 2012 /CNW Telbec/ - Sandoz Canada announces it has completed its re-inspection of all quarantined inventory of Morphine Sulfate Injection USP 2 mg/mL, 1 mL ampoules and is ...

Jan 26, 2012, 13:13 ET Sandoz launches (Pr)Sandoz* Losartan and Sandoz Losartan HCT

BOUCHERVILLE, QC, Jan. 26, 2012 /CNW Telbec/ - Sandoz announced the launch of Sandoz Losartan and Sandoz Losartan HCT, generic equivalents to Merck Frosst's Cozaar® and Hyzaar® in Canada. Sandoz...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE
Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected.